Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 4—April 2023
Research

Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5–11 Years of Age, Israel

Aharona Glatman-FreedmanComments to Author , Yael Hershkovitz, Rita Dichtiar, Alina Rosenberg, Lital Keinan-Boker, and Michal Bromberg
Author affiliations: Israel Center for Disease Control, Israel Ministry of Health, Ramat Gan, Israel (A. Glatman-Freedman, Y. Hershkovitz, R. Dichtiar, A. Rosenberg, L. Keinan-Boker, M. Bromberg); Tel Aviv University School of Public Health, Tel Aviv, Israel (A. Glatman-Freedman, M. Bromberg); Haifa University School of Public Health, Haifa, Israel (L. Keinan-Boker)

Main Article

Table 3

SARS-CoV-2–positive children 5–11 years of age hospitalized within 14 days of sampling, Israel

Total, no. (%), n = 78,541 Unvaccinated, no. (%), n = 63,710 Second-dose recipients, no. (%), n = 14,831 Variable
102 (0.13) 93 (0.15) 9 (0.06) Hospitalized
8 (0.01) 8 (0.01) 0 Severe/critical illness*
0 0 0 Died

*Severe Illness: oxygen saturation (SpO2) <94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mm Hg, respiratory rate >30 breaths/min, or lung infiltrates >50% (11). Critical Illness: respiratory failure, septic shock, and/or multiple organ dysfunction (11).

Main Article

References
  1. Food and Drug Administration. FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age [cited 2021 Dec 27]. https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age
  2. European Medicines Agency. Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11 [cited 2021 Dec 27]. https://www.ema.europa.eu/en/news/comirnaty-covid-19-vaccine-ema-recommends-approval-children-aged-5-11
  3. Walter  EB, Talaat  KR, Sabharwal  C, Gurtman  A, Lockhart  S, Paulsen  GC, et al.; C4591007 Clinical Trial Group. C4591007 Clinical Trial Group. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022;386:35–46. DOIPubMedGoogle Scholar
  4. Israel Ministry of Health. Ministry of Health Director General accepted the recommendation to vaccinate children 5 to 11 [cited 2021 Dec 27]. https://www.gov.il/en/departments/news/14112021-05
  5. Israel Ministry of Health. Vaccination appointments for children now available on HMOs [cited 2021 Dec 27]. https://www.gov.il/en/departments/news/22112021-01
  6. Wolter  N, Jassat  W, Walaza  S, Welch  R, Moultrie  H, Groome  M, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022;399:437–46. DOIPubMedGoogle Scholar
  7. Meo  SA, Meo  AS, Al-Jassir  FF, Klonoff  DC. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci. 2021;25:8012–8.
  8. Dejnirattisai  W, Huo  J, Zhou  D, Zahradník  J, Supasa  P, Liu  C, et al.; OPTIC Consortium; ISARIC4C Consortium. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185:467–484.e15. DOIPubMedGoogle Scholar
  9. Israel Ministry of Health. As of today, 27/11/2021, one confirmed case of the Omicron variant was detected in Israel [cited 2022 Jan 31]. https://www.gov.il/en/departments/news/27112021-01
  10. Our World in Data. SARS-CoV-2 variants in analyzed sequences, Israel [cited 2022 Mar 5]. https://ourworldindata.org/grapher/covid-variants-area?country=~ISR
  11. National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines [cited 2021 Jul 18]. https://www.covid19treatmentguidelines.nih.gov
  12. Central Bureau of Statistics. Statistical abstract of Israel 2021—no.72 [cited 2021 Nov 26]. https://www.cbs.gov.il/en/publications/Pages/2021/Population-Statistical-Abstract-of-Israel-2021-No.72.aspx
  13. Glatman-Freedman  A, Bromberg  M, Dichtiar  R, Hershkovitz  Y, Keinan-Boker  L. The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised data. EBioMedicine. 2021;72:103574. DOIPubMedGoogle Scholar
  14. Glatman-Freedman  A, Hershkovitz  Y, Kaufman  Z, Dichtiar  R, Keinan-Boker  L, Bromberg  M. Effectiveness of BNT162b2 vaccine in adolescents during outbreak of SARS-CoV-2 Delta variant infection, Israel, 2021. Emerg Infect Dis. 2021;27:2919–22. DOIPubMedGoogle Scholar
  15. Fowlkes  AL, Yoon  SK, Lutrick  K, Gwynn  L, Burns  J, Grant  L, et al. Effectiveness of 2-dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5-11 years and adolescents aged 12-15 years—PROTECT Cohort, July 202–-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71:422–8. DOIPubMedGoogle Scholar
  16. Tan  SHX, Cook  AR, Heng  D, Ong  B, Lye  DC, Tan  KB. Effectiveness of BNT162b2 vaccine against Omicron in children 5 to 11 years of age. N Engl J Med. 2022;387:525–32. DOIPubMedGoogle Scholar
  17. Cohen-Stavi  CJ, Magen  O, Barda  N, Yaron  S, Peretz  A, Netzer  D, et al. BNT162b2 Vaccine effectiveness against Omicron in children 5 to 11 years of age. N Engl J Med. 2022;387:227–36. DOIPubMedGoogle Scholar
  18. Fleming-Dutra  KE, Britton  A, Shang  N, Derado  G, Link-Gelles  R, Accorsi  EK, et al. Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during Omicron predominance. JAMA. 2022;327:2210–9. DOIPubMedGoogle Scholar
  19. Dorabawila  V, Hoefer  D, Bauer  UE, Bassett  MT, Lutterloh  E, Rosenberg  ES. Risk of infection and hospitalization among vaccinated and unvaccinated children and adolescents in New York after the emergence of the Omicron variant. JAMA. 2022;327:2242–4. DOIPubMedGoogle Scholar
  20. Sacco  C, Del Manso  M, Mateo-Urdiales  A, Rota  MC, Petrone  D, Riccardo  F, et al.; Italian National COVID-19 Integrated Surveillance System and the Italian COVID-19 vaccines registry. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022. Lancet. 2022;400:97–103. DOIPubMedGoogle Scholar
  21. Andrews  N, Stowe  J, Kirsebom  F, Toffa  S, Rickeard  T, Gallagher  E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022;386:1532–46. DOIPubMedGoogle Scholar
  22. Thompson  MG, Natarajan  K, Irving  SA, Rowley  EA, Griggs  EP, Gaglani  M, et al. Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance—VISION Network, 10 states, August 2021–January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:139–45. DOIPubMedGoogle Scholar
  23. Collie  S, Champion  J, Moultrie  H, Bekker  LG, Gray  G. Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa. N Engl J Med. 2022;386:494–6. DOIPubMedGoogle Scholar
  24. Buchan  SA, Chung  H, Brown  KA, Austin  PC, Fell  DB, Gubbay  JB, et al. Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. JAMA Netw Open. 2022;5:e2232760. DOIPubMedGoogle Scholar
  25. Nemet  I, Kliker  L, Lustig  Y, Zuckerman  N, Erster  O, Cohen  C, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N Engl J Med. 2022;386:492–4. DOIPubMedGoogle Scholar
  26. Chen  X, Huang  Z, Wang  J, Zhao  S, Wong  MC, Chong  KC, et al. Ratio of asymptomatic COVID-19 cases among ascertained SARS-CoV-2 infections in different regions and population groups in 2020: a systematic review and meta-analysis including 130 123 infections from 241 studies. BMJ Open. 2021;11:e049752. DOIPubMedGoogle Scholar
  27. Yonker  LM, Boucau  J, Regan  J, Choudhary  MC, Burns  MD, Young  N, et al. Virologic features of severe acute respiratory syndrome coronavirus 2 infection in children. J Infect Dis. 2021;224:1821–9. DOIPubMedGoogle Scholar
  28. Costa  R, Bueno  F, Albert  E, Torres  I, Carbonell-Sahuquillo  S, Barrés-Fernández  A, et al. Upper respiratory tract SARS-CoV-2 RNA loads in symptomatic and asymptomatic children and adults. Clin Microbiol Infect. 2021;27:1858.e1–7. DOIPubMedGoogle Scholar
  29. Israel Ministry of Health. Update of the testing and isolation policy regarding close contacts of a confirmed COVID-19 case, effective 7.1.2022 [cited 2021 Dec 27]. https://www.gov.il/en/departments/news/05012022-01

Main Article

Page created: February 08, 2023
Page updated: March 20, 2023
Page reviewed: March 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external